Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Capital Expenditures: 2015-2024

Historic Capital Expenditures for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $295,000.

  • UroGen Pharma's Capital Expenditures fell 9.38% to $87,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $387,000, marking a year-over-year increase of 15.18%. This contributed to the annual value of $295,000 for FY2024, which is 52.06% up from last year.
  • As of FY2024, UroGen Pharma's Capital Expenditures stood at $295,000, which was up 52.06% from $194,000 recorded in FY2023.
  • UroGen Pharma's 5-year Capital Expenditures high stood at $1.2 million for FY2020, and its period low was $194,000 during FY2023.
  • Over the past 3 years, UroGen Pharma's median Capital Expenditures value was $254,000 (recorded in 2022), while the average stood at $247,667.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 273.85% in 2020, then tumbled by 66.22% in 2022.
  • UroGen Pharma's Capital Expenditures (Yearly) stood at $1.2 million in 2020, then plummeted by 38.11% to $752,000 in 2021, then tumbled by 66.22% to $254,000 in 2022, then dropped by 23.62% to $194,000 in 2023, then spiked by 52.06% to $295,000 in 2024.